Compare Ginkgo Bioworks Holdings Inc (DNA) vs KLA Corp. (KLAC) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

KLA Corporation (KLAC) trades at $196.83, down 0.32% on the day, with strong technical support at $194 and resistance at $198. The company demonstrates robust fundamentals with revenue growth from $9.8B in 2024 to $12.16B in 2025 and net income margin expanding to 35.57%. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.05 surpassing the $1.00 estimate. AI-driven demand is fueling backlog growth to $12.57B, positioning KLAC for continued expansion in semiconductor equipment markets.

KLAC presents a compelling growth opportunity with strong analyst support (28 buys vs 2 sells) and a $223.88 consensus price target offering 14% upside. However, elevated valuation ratios (P/E 53.75, P/S 19.12) and competitive pressures from Applied Materials and ASML represent key risks. The stock's technical bullish signal and institutional accumulation support near-term momentum, though margin compression and semiconductor cycle volatility warrant monitoring.